(Q50754964)

English

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

scientific article published in January 1996

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 March 2018

http://europepmc.org/abstract/MED/8628543

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. (English)

1 reference

Europe PubMed Central

18 March 2018

http://europepmc.org/abstract/MED/8628543

open-angle glaucoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Watson P

1

1 reference

Europe PubMed Central

18 March 2018

http://europepmc.org/abstract/MED/8628543

Stjernschantz J

2

1 reference

Europe PubMed Central

18 March 2018

http://europepmc.org/abstract/MED/8628543

publication date

1 January 1996

1 reference

Europe PubMed Central

18 March 2018

http://europepmc.org/abstract/MED/8628543

1 reference

Europe PubMed Central

18 March 2018

http://europepmc.org/abstract/MED/8628543

103

1 reference

Europe PubMed Central

18 March 2018

http://europepmc.org/abstract/MED/8628543

1

1 reference

Europe PubMed Central

18 March 2018

http://europepmc.org/abstract/MED/8628543

126-137

1 reference

Europe PubMed Central

18 March 2018

http://europepmc.org/abstract/MED/8628543

Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2896%2930750-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2896%2930750-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2896%2930750-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2896%2930750-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2896%2930750-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2896%2930750-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2896%2930750-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2896%2930750-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2896%2930750-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2896%2930750-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2896%2930750-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F2 alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2896%2930750-1

7 January 2021

based on heuristic

inferred from DOI database lookup

PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2896%2930750-1

7 January 2021

based on heuristic

inferred from DOI database lookup

PhXA34--a prostaglandin F2 alpha analogue. Effect on intraocular pressure in patients with ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2896%2930750-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Timolol, dose response and duration of action

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2896%2930750-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency of timolol administration

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2896%2930750-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2896%2930750-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2896%2930750-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0161-6420(96)30750-1

1 reference

Europe PubMed Central

18 March 2018

http://europepmc.org/abstract/MED/8628543

1 reference

Europe PubMed Central

18 March 2018

http://europepmc.org/abstract/MED/8628543

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50754964&oldid=1561854676"